Jean Chidiac

The Clinical Course of Venous Thromboembolism May Differ According to Cancer Site

Isabelle Mahé, Jean Chidiac, Laurent Bertoletti et al. · The American Journal of Medicine · 2016 · 98 citations

Clinical Course, Thrombosis, Pulmonary Embolism +13

Whole blood clots are more resistant to lysis than plasma clots - greater efficacy of rivaroxaban

R. Varin, Shahsultan Mirshahi, Pezhman Mirshahi et al. · Thrombosis Research · 2013 · 90 citations

Thrombosis, Greater Efficacy, Whole Blood Clots +8

Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism

Isabelle Mahé, Marc Carrier, D. Mayeur et al. · New England Journal of Medicine · 2025 · 85 citations

Abstract S1-6: TAMRAD: A GINECO Randomized Phase II Trial of Everolimus in Combination with Tamoxifen Versus Tamoxifen Alone in Patients (pts) with Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer (MBC) with Prior Exposure to Aromatase Inhibitors (AI).

T Bachelot, C. Bourgier, Claire Cropet et al. · Cancer Research · 2010 · 61 citations

Breast Oncology, Pharmacotherapy, Endocrine Oncology +16

Endothelial protein C receptor expressed by ovarian cancer cells as a possible biomarker of cancer onset

E. Ducros, Shahsoltan Mirshahi, Dalel Azzazene et al. · International Journal of Oncology · 2012 · 36 citations · Full text

Immunology, Gynecology, Pathology +18